Cromwell Holdings LLC Has $121,000 Stock Holdings in DexCom, Inc. $DXCM

Cromwell Holdings LLC lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 20.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,383 shares of the medical device company’s stock after purchasing an additional 232 shares during the quarter. Cromwell Holdings LLC’s holdings in DexCom were worth $121,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of DXCM. Mirae Asset Global Investments Co. Ltd. boosted its position in DexCom by 6.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 190,693 shares of the medical device company’s stock worth $16,646,000 after acquiring an additional 12,155 shares during the last quarter. J. Safra Sarasin Holding AG boosted its position in DexCom by 153.8% during the 2nd quarter. J. Safra Sarasin Holding AG now owns 40,575 shares of the medical device company’s stock worth $3,542,000 after acquiring an additional 24,590 shares during the last quarter. Consolidated Portfolio Review Corp acquired a new position in DexCom during the 2nd quarter worth approximately $246,000. Capital Investment Advisors LLC acquired a new position in DexCom during the 2nd quarter worth approximately $248,000. Finally, SWS Partners acquired a new position in DexCom during the 2nd quarter worth approximately $1,661,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Trading Up 0.5%

Shares of DexCom stock opened at $66.44 on Friday. The business has a fifty day simple moving average of $76.75 and a two-hundred day simple moving average of $77.91. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $93.25. The company has a market capitalization of $26.05 billion, a price-to-earnings ratio of 46.14, a P/E/G ratio of 1.39 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the firm posted $0.43 EPS. The company’s quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on DXCM. Argus assumed coverage on DexCom in a research report on Thursday, August 21st. They set a “buy” rating and a $100.00 price target for the company. Piper Sandler increased their price objective on DexCom from $90.00 to $100.00 and gave the company an “overweight” rating in a report on Thursday, July 31st. Robert W. Baird cut their price objective on DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a report on Friday, September 26th. Barclays increased their price objective on DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Finally, Raymond James Financial increased their price objective on DexCom from $99.00 to $102.00 and gave the company a “strong-buy” rating in a report on Thursday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.32.

Insider Transactions at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director owned 22,667 shares in the company, valued at $1,832,853.62. This trade represents a 2.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president owned 105,223 shares in the company, valued at $8,417,840. The trade was a 1.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock worth $564,733 over the last quarter. 0.32% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.